Opinion: Sexual Dysfunction Matters

Desire and arousal disorders require the biopharmaceutical industry’s attention.

Written byRobert Pyke
| 3 min read

Register for free to listen to this article
Listen with Speechify
0:00
3:00
Share

FLICKR, JASON SCHLACHETA female commentator on a major cable news channel recently told viewers that the way for men to turn women “on” is to “load the dishwasher.” If it were that simple, therapists would have a great track record of treating low female libido. The dirty secret is they don't. And even more surprising secrets exist in the published research. For example, in 2011, a national survey determined that men who do domestic chores, the kind traditionally performed by women, have significantly less sex than men who don’t, not more.

Though pharmaceutical companies are commonly criticized for “medicalizing” sexual dysfunction, this is not the case. Sexual functioning levels are reduced, and sexual distress is increased among women with sexual desire or arousal problems who have reported a sexual complaint to a doctor—even those who reported otherwise-normal levels of marital satisfaction. Problems with desire and arousal are even recognized by the American Psychiatric Association (APA), which combines the two within sexual interest-arousal disorder (SI-AD). According to the APA, low desire is a problem worth treating when it causes distress and reduces the quality of a woman's life.

People diagnosed with hypoactive sexual desire disorder (HSDD) experience little to no desire for sex, and as a result, significant distress or interpersonal difficulties. Although under-diagnosed, HSDD is highly ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Related Topics

Meet the Author

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies